RE: Final overall survival: Fulvestrant 500mg vs 250mg in the randomized CONFIRM trial

  1. Martin, M.
  2. Boyer, J.
  3. Stuart, M.
  4. Di Leo, A.
Zeitschrift:
Journal of the National Cancer Institute

ISSN: 1460-2105,  0027-8874

Datum der Publikation: 2017

Ausgabe: 109

Nummer: 3

Art: Brief

DOI: 10.1093/JNCI/DJW234 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus